At the 2019 ASH Annual Meeting, many presented updated data on several emerging treatment modalities including bispecific t cell engagers. Oncology Nursing News interviewed Sandy W. Wong, MD, an assistant clinical professor in the Division of Hematology/Oncology, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center.
He told the publication:
"The BiTEs are really interesting. [Previously, there were] data on AMG 420, which was presented at the 2019 ASCO Annual Meeting. It's proof that this category of drugs can be effective in the relapsed/refractory setting. The response rate was great, but many patients suffered from neuropathy and infections, such as the astrogliosis and the adenovirus."
To read his full interview, visit Oncology Nursing News.